(Q54055764)

English

Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). (English)

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

phase II clinical trial

0 references

author name string

R Morant

1

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

J Bernhard

2

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

R Maibach

3

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

M Borner

4

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

M F Fey

5

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

B Thürlimann

6

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

E Jacky

7

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

F Trinkler

8

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

J Bauer

9

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

G Zulian

10

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

S Hanselmann

11

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

C Hürny

12

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

F Hering

13

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

publication date

1 February 2000

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

Annals of Oncology

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

11

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

2

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

183-188

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

Management of cancer of the prostate

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral estramustine and oral etoposide for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

THE USE OF PROSTATE-SPECIFIC ANTIGEN AS A SURROGATE END POINT IN THE TREATMENT OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum prostate-specific antigen: expanding its role as a measure of treatment response in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008332724977

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008332724977

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

1 reference

Europe PubMed Central

24 May 2018

http://europepmc.org/abstract/MED/10761753

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54055764&oldid=1612147134"